Treatment of acute leukemia--advances in chemotherapy, immunotherapy, and bone marrow transplantation.
D015250:Aclarubicin / Q000031:analogs & derivatives*; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000609:Aminoacridines / Q000627:therapeutic use; D000677:Amsacrine; D000880:Anthraquinones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal; D001374:Azacitidine / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D007167:Immunotherapy; D007223:Infant; D007372:Interferons / Q000627:therapeutic use; D007938:Leukemia / Q000401:mortality / Q000628:therapy*; D007945:Leukemia, Lymphoid / Q000628:therapy; D008081:Liposomes / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone; D009279:Naphthacenes / Q000627:therapeutic use; D011379:Prognosis; D013713:Teniposide / Q000627:therapeutic use; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014751:Vindesine
D000609:Aminoacridines; D000880:Anthraquinones; D000911:Antibodies, Monoclonal; D008081:Liposomes; D009279:Naphthacenes; C011157:aclacinomycins; D000677:Amsacrine; D014747:Vinblastine; D005047:Etoposide; D015250:Aclarubicin; D007372:Interferons; D013713:Teniposide; D008942:Mitoxantrone; D001374:Azacitidine; D014751:Vindesine; D007069:Ifosfamide